Antler Gold

Allreal Holding

Alarm.com Holdings

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

An analyst at Morgan Stanley is impressed with the device pipeline at&nbsp;Abbott Laboratories (NYSE: <a class="ticker" href="/stock/abt#NYSE">ABT</a>).
<h3>
	The Analyst</h3>
Morgan Stanley analyst <a href="https://www.tipranks.com/analysts/david-lewis">David Lewis</a> upgraded shares of Abbott Labs <a href="https://www.benzinga.com/analyst-ratings/upgrades/18/01/10972481/benzingas-top-upgrades-downgrades-for-january-2-2018">from Equal-Weight to Overweight</a> and lifted the price target from $60 to $67.
<h3>
	The Thesis</h3>
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/17/12/10904236/abbott-laboratories-makes-bmo-capitals-top-picks-list"> Abbott Lab&#39;s </a> device pipeline, notably Libre and Confirm, could drive an acceleration in organic revenue growth to 6-percent-plus in 2018, Lewis said in a Tuesday note (See the analyst&#39;s track record <a href="https://www.tipranks.com/analysts/david-lewis">here</a>.)
The pipeline strength coupled with <a href="https://www.bloomberg.com/news/articles/2017-04-14/abbott-said-to-agree-to-buy-alere-at-lower-price-of-51-shr-ft"> deal synergies </a> could lead to mid-teens earnings per share growth through 2019, Lewis said.
Abbott&#39;s risk-reward reverses in 2018, Lewis said, helped by fading of the regulatory issues with St Jude Medical Inc (NYSE: <a class="ticker" href="/stock/stj#NYSE">STJ</a>), Alere Inc (NYSE: <a class="ticker" href="/stock/alr#NYSE">ALR</a>) returning to stable revenue in 2018, China Pediatric Nutrition resuming double-digit growth and the alleviation of balance sheet concerns.
&quot; ... As risks fade, we see an emerging picture of top-tier growth that is not captured in Street expectations for 2018,&quot; Lewis said.&nbsp;
&quot;We see multiple expansion on Abbott&#39;s premium profile and improving leverage driving outperformance.&quot;
<h3>
	The Price Action</h3>
Abbott Labs shares are up over 53 percent over the past year.
At the time of writing, the shares were running up 2.85 percent to $58.73.
Related Links:
<a href="https://www.benzinga.com/news/17/04/9298352/abbott-takes-action-on-fda-warning-letter"> Abbott Takes Action On FDA Warning Letter </a>
<a href="https://www.benzinga.com/general/biotech/17/10/10156084/dexcoms-quiet-consolidation-after-huge-decline"> DexCom&#39;s Quiet Consolidation After Huge Decline </a>
Photo courtesy of Abbott Laboratories.&nbsp;

Analyst Color

Upgrades

Health Care

Price Target

Analyst Ratings

General

Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Friday. September 29. through Sunday. October 1, 2017.
Abbott, Alere Merger Set To Close Friday October, 3rd 2017
The Closing:
Alere Inc (NYSE: <a class="ticker" href="/stock/alr#NYSE">ALR</a>) announced Friday that Abbott Laboratories (NYSE: <a class="ticker" href="/stock/abt#NYSE">ABT</a>) acquisition of Alere will close on October 3, 2017. All necessary regulatory clearances have been receives for closing and Alere&#39;s common will cease trading on the NYSE stock before the market open on October 3, 2017.
Alere shares closed Friday at $50.99, up 25 cents.
US Concrete to Acquire Polaris Materials for C$3.40/Share in Cash
The Deal:
U.S. Concrete, Inc. (NASDAQ: <a class="ticker" href="/stock/uscr#NASDAQ">USCR</a>) announced it has entered into an agreement with Polaris Materials Corporation (OTC: <a class="ticker" href="/stock/polmf#OTC">POLMF</a>), under which U.S. Concrete will acquire all the issued and outstanding common shares of Polaris for C$3.40 per share in cash. Due to the superior offer from USCR, Polaris has terminated the previously announced arrangement agreement between Polaris, Vulcan Materials Company (NYSE: <a class="ticker" href="/stock/vmc#NYSE">VMC</a>) and a wholly-owned subsidiary of Vulcan dated August 25, 2017.
U.S. Concrete closed at $76.30, up $0.70.
Ecolab to Acquire Georgia-Pacific Paper Chemicals Business
The Deal:
Ecolab Inc. (NYSE: <a class="ticker" href="/stock/ecl#NYSE">ECL</a>) signed an agreement to acquire the paper chemicals business, which supplies differentiated products and applications that provide strength, softness and durability to paper, from Georgia-Pacific. Terms of the transaction, which is expected to be completed before the end of the year, were not disclosed.
Ecolab closed at $128.61, down 66 cents.
CRH Near Acquisition of Suwannee American Cement for $750M
The Rumor:
CRH Plc (ADR) (NYSE: <a class="ticker" href="/stock/crh#NYSE">CRH</a>) is close to a deal to acquire Suwannee American Cement LLC from Votorantim Cimentos SA and Anderson Columbia Co. for $750 million, according to a report from Bloomberg on Sunday. An agreement could be announced this week.
CRH closed at $37.86, up 58 cents.
Nordstrom Going Private Talks Could Fall Apart
The Rumor:
Talks aimed at taking Nordstrom, Inc. (NYSE: <a class="ticker" href="/stock/jwn#NYSE">JWN</a>) private are said to be at risk of collapsing, according to a report from the New York Post on Sunday. The Nordstrom family has been having difficulty securing financing for the deal, which could be valued at $10 billion, due to the recent Toys &#39;R&#39; Us bankruptcy filing, sources said.
Leonard Green had been in talks to finance $1 billion and was expecting to make a decision by the end of September, a source said
Nordstrom closed at $47.15, down $0.25.

News

Rumors

POLMF

USCR

Wall Street's M&A Chatter From Sept. 26-Oct. 1: Nordstrom, US Concrete, Ecolab And More

Alere Reports Received FDA Clearance For Co.'s i Influenza A, B 2 Rapid Molecular Test

Abbott, Alere Acquisition Set To Close Tuesday Oct. 3rd 2017

Alere Inc. (NYSE: <a class="ticker" href="/stock/alr#NYSE">ALR</a>) announced Thursday, that it has reached an agreement in principle to settle with the U.S. Department of Justice (the "DOJ") to resolve various potential civil claims, including claims under the False Claims Act, relating to Alere Triage® cardiac and Toxicology products sold between January 2006 and March 31, 2012. The settlement relates to matters arising out of the previously disclosed 2012 FDA inspection of Alere San Diego and the Office of Inspector General subpoena.
Alere issued the following statement:
We have cooperated with the DOJ investigation, and we are pleased to reach this agreement in principle that would fully resolve this matter with DOJ.
If the ongoing discussions with the DOJ are successfully concluded, we believe the total combined payment to the Department of Justice and the participating states will be within the $35 million loss contingency reserve previously taken by the Company.

Legal

Alere Announces Agreement in Principle to Settle with DoJ

QDEL

Quidel Issues Release Highlighting Early Termination Of HSR Waiting Period Related To Pending Purchase Of Alere's Triage BNP Assay Unit

Asset Sales

Movers

Alere Shares Spike To Session Highs Up 3.5% As FTC Says Abbott Labs Must Divest 2 Types Of Point-Of-Care Medical Testing Devices As Part Of Acquiring Alere

UPDATE: Alere To Pay $13M To SEC In Connection With Previously Disclosed Investigation Regarding Accounting Fraud And Improper Payments To Foreign Officials

Alere Shares Volatile Here As SEC Says Co. Unit Has Settled Accounting Fraud Charges

Analysts at Piper Jaffray turned bullish on Quidel Corporation (NASDAQ: <a class="ticker" href="/stock/qdel#NASDAQ">QDEL</a>), mostly due to the company's "sweetening" of its already attractive Alere Inc (NYSE: <a class="ticker" href="/stock/alr#NYSE">ALR</a>) <A href="https://www.360dx.com/business-news/quidel-amends-acquisition-alere-bnp-assay-business">asset acquisition.</a> The firm's <a href="https://www.tipranks.com/analysts/william-quirk">William R. Quirk</a> upgrades <A href="https://www.benzinga.com/stock/qdel">Quidel's stock rating</a> from Neutral to Overweight with a price target boosted from $35 to $50.
Quidel, a diagnostics maker, announced in July it would buy <A href="https://www.benzinga.com/general/biotech/17/01/8946267/the-timeline-of-a-contentious-history-abbott-and-alere">Alere's triage assets</a> but on Monday announced it has revised the agreement to now include the full worldwide BNP business, Quirk highlighted. While the revised deal implies an additional $48 million in BNP revenue, more importantly, the deal will add $50 million to $60 million in EBITDA. In fact, the entire deal could now boost Quidel's annual EBITDA by around $100 million.
The analyst's 2018 earnings per share estimate were also moved higher by 64 percent to $1.34 per share and then rise another 41 percent in fiscal 2019.
"Whether it is luck or being at the right place at the right time, we believe Quidel has done it again and sweetened its already attractive Alere deal," the analyst emphasized.
Looking forward, Quidel's stock is expected to move higher as investors begin to digest the revised deal and accretion estimates, the analyst added. As such, a new multiple of 4x 2018 EV/pro forma revenue is appropriate as opposed to a prior 3x multiple which derives the analyst's new $50 price target.
At last check, shares of Quidel were up 8.12 percent at $44.23.
Related Links:
<A href="https://www.benzinga.com/news/17/09/10074630/mid-morning-market-update-markets-edge-higher-autozone-earnings-top-expectations">Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations</a>
<A href="https://www.benzinga.com/analyst-ratings/upgrades/17/09/10074328/benzingas-top-upgrades-downgrades-for-september-19-2017">Benzinga's Top Upgrades, Downgrades For September 19, 2017</a>

Biotech

Long Ideas

Tech

Trading Ideas

Piper Jaffray Says Quidel Shares Can Continue To Rise On The Back Of New Deal With Alere

Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere at $402/Share

Transaction Highlights:
<ul>
<li>Parties entered into amended and restated agreements for Quidel&rsquo;s acquisition of both businesses. Business arrangement of previously announced transaction to purchase the Triage&reg; MeterPro cardiovascular and toxicology assets from Alere Inc. remains substantially unchanged.</li>
<li>Revised BNP acquisition agreement provides Quidel direct commercial responsibility after the purchase for all sales globally of Alere&rsquo;s BNP assay business run on Beckman Coulter analyzers.</li>
<li>The total cash consideration for both businesses will now be up to $680 million, comprised of the previously announced $400 million purchase price for the Triage business, $40 million in contingent consideration and $240 million in deferred consideration for the BNP business.</li>
<li>Accretive transactions designed to extend Quidel&rsquo;s market leadership and position it for future growth.</li>
</ul>
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ:<a class="ticker" href="/stock/QDEL#NASDAQ">QDEL</a>) (&ldquo;Quidel&rdquo;), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced a revised definitive agreement with Alere Inc. for its pending acquisition of Alere&rsquo;s BNP assay business run on Beckman Coulter analyzers (&ldquo;BNP business&rdquo;) under which post-acquisition Quidel will undertake direct commercial responsibility for all such BNP sales globally, while the pending acquisition of Alere&rsquo;s Triage&reg; MeterPro cardiovascular (CV) and toxicology assets (&ldquo;Triage business&rdquo;) remains substantially unchanged. These businesses are being divested by Alere pending antitrust approvals required for Abbott&rsquo;s pending acquisition of Alere. The acquisitions by Quidel are subject to the completion of Abbott&rsquo;s acquisition of Alere, as well as regulatory approvals and other customary closing conditions. Estimated trailing twelve-month revenues through June 2017 for the BNP business under the revised deal terms were $107 million. Total actual revenues for all of the acquired businesses in 2016 was $245 million compared to $197 million under the previously structured transactions. The transactions will be funded through a combination of cash on hand and committed financing. Quidel now expects the transactions to close within 30 days after Abbott&rsquo;s close of the Alere acquisition, which is expected to occur by September 30, 2017. &ldquo;Through the updated acquisition agreements, we will undertake direct commercial responsibility for the BNP assay business globally, representing an enhanced revenue and EBITDA contribution opportunity post-close. We believe that we are on track to close the acquisition of the Triage and BNP businesses within 30 days of Abbott&rsquo;s close of the Alere acquisition,&rdquo; stated&nbsp;Douglas Bryant, president and chief executive officer of&nbsp;Quidel Corporation. &ldquo;We believe there are substantial benefits to be realized as we bring these strong businesses together, further establishing Quidel&rsquo;s platform for growth and shareholder value creation opportunities.&rdquo; Summary Terms of Acquisition Agreements and Financing Quidel will acquire the Triage business, including real estate for the San Diego Triage facilities, and the global BNP business for a total consideration of up to $680 million, comprised of the previously announced $400 million purchase price for the Triage business, $40 million in contingent consideration for the EEA BNP business, and $240 million in deferred consideration for the rest-of-world BNP business. The company expects to finance the acquisitions with cash plus committed financing from Bank of America Merrill Lynch and J.P. Morgan Chase Bank. The transactions are subject to other terms and conditions set forth in the acquisition agreements, which Quidel will file shortly with the SEC on Form 8-K.

Quidel Announces a Revised Agreement for the Acquisition of Alere's B-Type Naturietic Peptide, Says Previous Agreement is Substantially Unchanged, Total Cash Consideration will be up to $680M

Hedge Funds

13F From Einhorn's Greenlight Shows Liquidated Position In Alere

Earnings

Alere Reports Q2 GAAP EPS $(1.13) vs $(0.44) In Same Qtr. Last Year

Alere Subsidiary Immunalysis Receives FDA Clearance for SEFRIA Fentanyl Urine Drug Screening Test

Contracts

Alere Entered Into Purchase Agreement With Siemens Diagnostics Holdings

Alere Launches Alere iCup Rx Drug Screen for Detecting Commonly Misused and Abused Prescription Drugs

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Monday, July 17, 2017.
Washington Cos. to Acquire Dominion Diamond for $14.25/Share in Cash
The Deal:
Dominion Diamond Corp (NYSE: <a class="ticker" href="/stock/ddc#NYSE">DDC</a>) and The Washington Companies have entered into an arrangement agreement under which an entity affiliated with Washington will acquire all of Dominion&#39;s outstanding common shares for $14.25 per share in cash, for a total equity value of approximately $1.2 billion. The transaction is expected to close in Q4 of 2017, subject to the approval of at least two-thirds of the votes cast at a special meeting of Dominion shareholders.
Dominion Diamond closed at $14.07, up 59 cents.
Church &amp; Dwight Acquire Waterpik for $1B Cash
The Deal:
Church &amp; Dwight Co., Inc. (NYSE: <a class="ticker" href="/stock/chd#NYSE">CHD</a>) has signed a definitive agreement to acquire Water Pik, Inc. for approximately $1 billion in cash. The transaction is expected to close in Q3 2017.
Church &amp; Dwight closed at $53.33, up 71 cents.
Quidel to Acquire Alere Triage Assets for $400M Plus $40M in Contingent Consideration
The Deal:
Quidel Corporation (NASDAQ: <a class="ticker" href="/stock/qdel#NASDAQ">QDEL</a>) has entered into definitive agreements to acquire the Triage business and the BNP business from Alere Inc. (NYSE: <a class="ticker" href="/stock/alr#NYSE">ALR</a>) for a total consideration of $400 million plus $40 million in contingent consideration.
The businesses are being divested in order to obtain antitrust approvals for Abbott&rsquo;s (NYSE: <a class="ticker" href="/stock/abt#NYSE">ABT</a>) pending acquisition of Alere.
Quidel closed at $34.12, up $6.90.
BorgWarner to Acquire Sevcon for $22/Share in Cash
The Deal:
BorgWarner Inc. (NYSE: <a class="ticker" href="/stock/bwa#NYSE">BWA</a>) has entered into a definitive agreement to acquire electrification technologies company Sevcon Inc (NASDAQ: <a class="ticker" href="/stock/sev#NASDAQ">SEV</a>) for $22.00 per share in cash, for an enterprise value of approximately $200 million. The transaction is expected to close in Q4 of 2017.
Sevcon closed at $21.73, up $8.13.

Wall Street's M&A Chatter From July 17: BorgWarner-Sevcon, Church & Dwight-Waterpik, Quidel-Alere Triage

ABBOTT PARK, Ill., July 17, 2017 /PRNewswire/ --&nbsp;Abbott (NYSE:<a class="ticker" href="/stock/ABT#NYSE">ABT</a>) announced today that it is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the &quot;Preferred Stock&quot;) of Alere Inc. (&quot;Alere&quot;) at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the &quot;Offer&quot;). The Offer is being made pursuant to an Offer to Purchase, dated July 17, 2017 (the &quot;Offer to Purchase&quot;), and in connection with Abbott&#39;s previously announced agreement to acquire Alere (the &quot;Merger&quot;). The Merger is not conditioned upon, or otherwise subject to, the completion of the Offer. The Offer, however, is conditioned upon the consummation of the Merger in accordance with the terms of the Merger Agreement.

Abbott Commences Cash Offer for Series B Convertible Preferred Stock for $402/Share

Alere Shareholders Approve Amended Merger with Abbott For $51/Share Cash

Recent Quotes

Related Companies

undefined Frequently Asked Questions

How do I buy undefined (ALR) stock?

Who are undefined's (ALR) competitors?

What is the target price for undefined (ALR) stock?

Current Stock Price for undefined (ALR)?

Does undefined (ALR) pay a dividend?

When is undefined (undefined:ALR) reporting earnings?

Is undefined (ALR) going to split?

What sector and industry does undefined (ALR) operate in?